Tvardi Therapeutics
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3 Sugar Creek Center Blvd Ste 525, Sugar...Phone Number
(713) 489-8654Website
www.tvarditherapeutics.comRevenue
-Stock Symbol
TVRDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Tvardi Therapeutics
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company operating in the biotechnology and drug development industry, headquartered in Houston, Texas. The company focuses on developing novel, oral small molecule therapies targeting STAT3, a transcription factor central to fibrotic and cancer-related signaling pathways, to treat inflammatory and fibrosis-driven diseases with significant unmet medical need. Its pipeline includes STAT3 inhibitors TTI-101 and TTI-109, currently in clinical development for conditions such as hepatocellular carcinoma.Explore more
Tvardi Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tvardi Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Tvardi Therapeutics is spiking on competitors!
Tvardi Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Tvardi Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Tvardi Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Tvardi Therapeutics
Funding: Get notified immidiatlly once Tvardi Therapeutics has new funding data
Earning: See what the market has to say on Tvardi Therapeutics recently announced quarterly report
Product Launch: Get notified when Tvardi Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Tvardi Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Tvardi Therapeutics
Compare insights from companies similar to Tvardi Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tvardi Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tvardi Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tvardi Therapeutics.
Tvardi Therapeutics financials insights
Gather financial insights about Tvardi Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$9M
2020
Grant
$5M
2021
Series B
$74M
Tvardi Therapeutics Tech Stack
A closer look at the technologies used by Tvardi Therapeutics
See more technologies
Most Recent Scoops
Project
Tvardi Therapeutics has reported Phase I oncology clinical data for TTI-101 demonstrating target engagement, including a median 55% reduction in activated STAT3 via paired biopsies, a 79% reduction among patients achieving stable disease, and a 100% response rate in patients with elevated baseline activated STAT3 within approximately six weeks.
Medical Research, Clinical Operations
Project
Tvardi Therapeutics has reported preclinical data from a DSS colitis model showing that STAT3 inhibitor-treated murine colons were essentially indistinguishable from healthy controls in colon length and architecture, with a third-party literature comparison indicating 90% recovery on colon length and colonic inflammation score, outperforming approved tofacitinib and other direct STAT3 candidates tested in the same model.
Medical Research, Pharmaceuticals
Project
Tvardi Therapeutics has reported data from the REVERT Phase II study of TTI-101 in idiopathic pulmonary fibrosis, showing a greater than fourfold difference versus placebo in the slope of IL-6 and a seven percentage point improvement versus placebo in fibrosis score at 12 weeks, representing a decrease from baseline not previously reported in any other IPF trial within that timeframe.
Medical Research, Pharmaceuticals
Project
Tvardi Therapeutics has reported new immune modulation data from the TTI-109 Phase I healthy volunteer study, showing downregulation across 16 cellular and humoral immune subsets recognized as pathologic markers of inflammatory and proliferative disease, with key markers reduced by up to 60% and a consistent directional pattern observed across all three active dose levels, yielding a probability of less than 1 in 65,000 that the results occurred by random fluctuation.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Tvardi Therapeutics News & Media
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populationsTvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it will host a KOL webinar on Wednesday, August 19, 2026 at 11:00 AM ET featuring Randy Longman, MD, PhD (Weill Cornell Medicine), who will join Tvardi management to discuss the current treTvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodelingTvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement July 7,...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Tvardi Therapeutics
Sign Up For FreeTo access detailed company insights
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company operating in the biotechnology and drug development industry, headquartered in Houston, Texas. The company focuses on developing novel, oral small molecule therapies targeting STAT3, a transcription factor central to fibrotic and cancer-related signaling pathways, to treat infl... Read More
